FDA Needs Stronger Postmarket Reporting Process For Approved Drugs – Poll
This article was originally published in The Tan Sheet
Executive Summary
Approximately 70% of Americans favor bolstering FDA's postmarketing review of drugs and medical devices that are linked to adverse events, according to a recent poll